The First Crispr Treatment Is Making Its Way to Patients
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
EurekAlert!2d
Indonesian Thalassemia Survivor: "I've broken the inheritance chain of thalassemia"
Stanley Joewono is an Indonesia social media influencer and exercise enthusiast. Diagnosed with thalassemia at just 8 months ...
pharmaphorum2d
bluebird seeks gene therapy trial restart after cancer scare
Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
manilatimes1d
Two New Solutions from Hemex Health Empower More Clinicians and Health Workers to Test for Iron Deficiency Anaemia and Sickle Cell Disease
A next generation Snap Cartridge, part of the Gazelle™ S-10B Hb Variant Test Multipack, will simplify sample preparation so ...
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s ...
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...